baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Grifols SA/ ES0171996087 /

3/31/2023 5:29:48 PM	Chg. -0.05	Volume	Bid5:30:00 PM	Ask5:30:00 PM	Market Capitalization	Dividend Y.	P/E Ratio
9.10EUR	-0.54%	703,562 Turnover: 2.58 mill.	-Bid Size: -	-Ask Size: -	7.52 bill.EUR	1.76%	10.12

GlobeNewswire 3/11/2022 Synthetic Biologics Completes Acquisition of VCN Biosciences

GlobeNewswire 2/8/2022 Rain Therapeutics Continues to Strengthen its Leadership Team with Key Appointments

GlobeNewswire 11/1/2021 BioCryst Appoints Jinky Ang Rosselli Chief Data and Insights Officer

GlobeNewswire 10/20/2021 Opus Genetics Announces Two Key Leadership Appointments

GlobeNewswire 10/5/2021 Certara Appoints Drayton T. Virkler as Chief Commercial Officer

GlobeNewswire 9/30/2021 GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mo...

GlobeNewswire 8/11/2021 GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-205...

GlobeNewswire 7/28/2021 Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer

GlobeNewswire 7/14/2021 GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its ant...

GlobeNewswire 5/25/2021 GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 The...

GlobeNewswire 5/14/2021 Ferroglobe Announces New Appointments and Changes to the Board of Directors

GlobeNewswire 4/15/2021 GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology

GlobeNewswire 4/2/2021 Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating ...

GlobeNewswire 3/23/2021 GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual...

GlobeNewswire 3/8/2021 Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Co...

GlobeNewswire 9/15/2020 Stifel Bolsters Healthcare Services Investment Banking Team With Three New Managing Directors

TeleTrader 7/28/2020 Grifols says its anti-COVID-19 therapeutics ready for trials

GlobeNewswire 7/9/2020 Alkahest Provides Corporate Update

GlobeNewswire 6/1/2020 Alkahest Announces Initiation of Phase 2 Study AKST1210-201 Exploring Treatment of Cognitive Impairm...

GlobeNewswire 5/28/2020 Lumos Pharma Reports First Quarter 2020 Results and Provides Update on Clinical and Corporate Activi...

GlobeNewswire 4/24/2020 Lumos Pharma Hires Biotech Veteran Aaron Schuchart as Chief Business Officer

GlobeNewswire 3/30/2020 GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19

GlobeNewswire 2/10/2020 Alkahest Announces Initiation of Phase 2b Clinical Trial of AKST4290 in Patients with Treatment-Naïv...

GlobeNewswire 2/4/2020 Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in Parkinson’s Disease with Funding from The...

GlobeNewswire 1/15/2020 BioCryst Strengthens Commercial Rare Disease Leadership

Grifols SA/ ES0171996087 /

If you wish to receive reply to your feedback, please provide your email address.